Tecnis Eyhance, Tecnis Eyhance toric II IOLs approved by FDA
The FDA approved the Tecnis Eyhance and Tecnis Eyhance toric II IOLs for the treatment of patients with cataract, according to a press release.
The monofocal IOLs offer extended depth of focus, better image contrast in low-light environments and a new delivery system, protecting against contamination and streamlining delivery, the release said.
“Built on the proven Tecnis platform, Tecnis Eyhance combines low-light performance with breakthrough refractive surface design, providing a new kind of monofocal experience for cataract patients,” Rajesh K. Rajpal, MD, chief medical officer and global head of clinical and medical affairs at Johnson & Johnson Vision, said in the release.
The Eyhance launched in Europe in 2019 and in Canada and Latin America in 2020. The Eyhance toric II will launch in Canada and Europe later this year, the release said.
Read more about